Medicines For Europe has collaborated with IQVIA to analyze the pros and cons of national biosimilar medicine policies and test market sustainability by issuing scorecards that assess the level of competition, price evolution and volume development for seven key biologic molecules – adalimumab, etanercept, infliximab, insulin glargine, insulin lispro, rituximab and trastuzumab – across 12 European countries.
European Industry Backs Biosimilars ‘Scorecards’
Ratings Provide Analyses Of Biosimilar Policies In 12 Countries
Medicines for Europe and IQVIA have partnered to test biosimilar sustainability in 12 European countries by issuing scorecards that measure the contribution of a country’s biosimilar policies to health systems.
